JP6974487B2 - ４員ヘテロ環式アミドを含むｊａｋ阻害剤 - Google Patents

４員ヘテロ環式アミドを含むｊａｋ阻害剤 Download PDF

Info

Publication number
JP6974487B2
JP6974487B2 JP2019548449A JP2019548449A JP6974487B2 JP 6974487 B2 JP6974487 B2 JP 6974487B2 JP 2019548449 A JP2019548449 A JP 2019548449A JP 2019548449 A JP2019548449 A JP 2019548449A JP 6974487 B2 JP6974487 B2 JP 6974487B2
Authority
JP
Japan
Prior art keywords
compound
lung
pharmaceutically acceptable
pneumonia
transplant rejection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019548449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510015A (ja
JP2020510015A5 (enExample
Inventor
ポール アール． ファザリー，
ゲイリー イー．エル． ブラント，
キャメロン スミス，
スティーブン ディー．イー． サリバン，
オーデン， ロリ ジーン バン
メラニー エー． クラインシェック，
グレン ディー． クレーター，
Original Assignee
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー filed Critical セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー
Publication of JP2020510015A publication Critical patent/JP2020510015A/ja
Publication of JP2020510015A5 publication Critical patent/JP2020510015A5/ja
Application granted granted Critical
Publication of JP6974487B2 publication Critical patent/JP6974487B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
JP2019548449A 2017-03-09 2018-03-08 ４員ヘテロ環式アミドを含むｊａｋ阻害剤 Active JP6974487B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469073P 2017-03-09 2017-03-09
US62/469,073 2017-03-09
PCT/US2018/021489 WO2018165392A1 (en) 2017-03-09 2018-03-08 Jak inhibitors containing a 4-membered heterocyclic amide

Publications (3)

Publication Number Publication Date
JP2020510015A JP2020510015A (ja) 2020-04-02
JP2020510015A5 JP2020510015A5 (enExample) 2021-04-01
JP6974487B2 true JP6974487B2 (ja) 2021-12-01

Family

ID=61683956

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019548449A Active JP6974487B2 (ja) 2017-03-09 2018-03-08 ４員ヘテロ環式アミドを含むｊａｋ阻害剤
JP2019548369A Expired - Fee Related JP7134990B2 (ja) 2017-03-09 2018-03-08 縮合イミダゾ－ピペリジンｊａｋ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019548369A Expired - Fee Related JP7134990B2 (ja) 2017-03-09 2018-03-08 縮合イミダゾ－ピペリジンｊａｋ阻害剤

Country Status (20)

Country Link
US (10) US10208040B2 (enExample)
EP (2) EP3592743A1 (enExample)
JP (2) JP6974487B2 (enExample)
KR (2) KR102526764B1 (enExample)
CN (2) CN110461839B (enExample)
AR (2) AR111241A1 (enExample)
AU (2) AU2018231032B2 (enExample)
BR (2) BR112019018648A2 (enExample)
CA (1) CA2997772A1 (enExample)
DK (1) DK3592742T3 (enExample)
EA (2) EA037261B1 (enExample)
ES (1) ES2882186T3 (enExample)
IL (2) IL268689B2 (enExample)
MX (2) MX388750B (enExample)
PH (2) PH12019501941A1 (enExample)
PT (1) PT3592742T (enExample)
SG (2) SG11201907840RA (enExample)
TW (2) TWI754019B (enExample)
WO (2) WO2018165395A1 (enExample)
ZA (2) ZA201905585B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI710560B (zh) 2015-11-03 2020-11-21 美商施萬生物製藥研發Ｉｐ有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物
EP3831830A1 (en) * 2015-11-03 2021-06-09 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
TWI754019B (zh) * 2017-03-09 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 含有4員雜環醯胺之jak抑制劑
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AU2018261588A1 (en) 2017-05-01 2019-10-31 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
DK3837258T3 (da) * 2018-09-04 2024-07-22 Theravance Biopharma R&D Ip Llc Dimethyl amino azetidine amides as jak inhibitors
BR112021004087A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc processo para preparar inibidores de jak e seus intermediários
BR112021004063A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas heterocíclicas com 5 a 7 membros como inibidores de jak
EP3853229A1 (en) 2018-10-29 2021-07-28 Theravance Biopharma R&D IP, LLC 2-azabicyclo hexane compound as jak inhibitor
KR102873783B1 (ko) 2019-02-25 2025-10-21 메디노 파마슈티컬 테크놀로지 (주하이) 컴퍼니 리미티드 Jak 억제제 화합물 및 그 사용
US12698289B2 (en) 2019-02-25 2026-08-04 Henan Medinno Pharmaceutical Technology Co., Ltd. Solid forms of pharmaceutically acceptable salts of (S)-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-4,6-dihydropyrrolo[3,4-d]imidazol-5(1H)-yl)(3-hydroxypyrrolidin-1-yl)methanone as JAK inhibitors
UA130579C2 (uk) 2019-03-05 2026-03-25 Інсайт Корпорейшн Інгібітори шляхів jak1 для лікування хронічної дисфункції алотрансплантата легень
CN114901659A (zh) * 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
JP7580136B2 (ja) * 2019-12-30 2024-11-11 路良 Ｊａｋ阻害剤化合物及びその使用
KR20220149585A (ko) 2020-03-02 2022-11-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제 화합물의 결정성 수화물
EP3944859A1 (en) * 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022178215A1 (en) * 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
TW202317550A (zh) * 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
CN118401508A (zh) * 2021-12-17 2024-07-26 株式会社大熊制药 (2R,3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新酸加成盐及晶形
CN117658852B (zh) * 2023-11-15 2026-03-24 西北工业大学 取代苯氧乙酰肼类化合物及其制备方法和作为stat3的抗炎抑制剂的应用
WO2025157904A1 (en) * 2024-01-24 2025-07-31 Kiox Pharmaceuticals Aps Inhalable formulations of ruxolitinib, methods of manufacture and uses thereof
CN118903009B (zh) * 2024-10-11 2025-01-21 江苏长泰药业股份有限公司 一种调节呼吸道微生态的丙酮酸钠气雾剂及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
CA2756989A1 (en) 2009-04-03 2010-10-07 Douglas Burdi Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
SMT201700581T1 (it) 2009-12-21 2018-01-11 Samumed Llc 1h-pirazolo[3,4-b]piridine e loro usi terapeutici
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2771340B1 (en) 2011-10-25 2016-04-13 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
LT3077395T (lt) 2013-12-05 2018-02-12 Pfizer Inc. Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
PE20161475A1 (es) 2014-05-14 2017-01-08 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
EP3831830A1 (en) * 2015-11-03 2021-06-09 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
DK3712152T3 (da) 2015-11-03 2021-03-22 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
TWI710560B (zh) 2015-11-03 2020-11-21 美商施萬生物製藥研發Ｉｐ有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物
TWI754019B (zh) * 2017-03-09 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 含有4員雜環醯胺之jak抑制劑
EP3619208B1 (en) 2017-05-01 2023-06-07 Theravance Biopharma R&D IP, LLC Crystalline forms of a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AU2018261588A1 (en) 2017-05-01 2019-10-31 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
DK3837258T3 (da) 2018-09-04 2024-07-22 Theravance Biopharma R&D Ip Llc Dimethyl amino azetidine amides as jak inhibitors
BR112021004063A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas heterocíclicas com 5 a 7 membros como inibidores de jak
BR112021004087A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc processo para preparar inibidores de jak e seus intermediários

Also Published As

Publication number Publication date
MX2019010539A (es) 2019-10-21
NZ756823A (en) 2021-04-30
US10392386B2 (en) 2019-08-27
PH12019501985A1 (en) 2020-10-05
US10954237B2 (en) 2021-03-23
CN110461839A (zh) 2019-11-15
SG11201907840RA (en) 2019-09-27
US11667637B2 (en) 2023-06-06
US20180258087A1 (en) 2018-09-13
EA201992128A1 (ru) 2020-01-29
EA037261B1 (ru) 2021-03-01
TWI754019B (zh) 2022-02-01
WO2018165395A1 (en) 2018-09-13
IL268689B (en) 2022-10-01
AU2018231032B2 (en) 2021-08-19
JP2020510010A (ja) 2020-04-02
US20230063643A1 (en) 2023-03-02
AR111241A1 (es) 2019-06-19
DK3592742T3 (da) 2021-08-09
KR102526764B1 (ko) 2023-04-27
US20180258088A1 (en) 2018-09-13
US20210269436A1 (en) 2021-09-02
US10519153B2 (en) 2019-12-31
MX388749B (es) 2025-03-11
EA201992126A1 (ru) 2020-02-05
IL268689A (en) 2019-10-31
US11878977B2 (en) 2024-01-23
US10196393B2 (en) 2019-02-05
SG11201907544VA (en) 2019-09-27
BR112019018648A2 (pt) 2020-06-16
CN110382498B (zh) 2022-07-12
TW201840560A (zh) 2018-11-16
US20200216447A1 (en) 2020-07-09
TW201837037A (zh) 2018-10-16
AU2018231032A1 (en) 2019-09-05
IL268689B2 (en) 2023-02-01
US20190119275A1 (en) 2019-04-25
US20200181141A1 (en) 2020-06-11
ES2882186T3 (es) 2021-12-01
BR112019018649A2 (pt) 2020-04-07
PH12019501941A1 (en) 2020-07-06
US20190337945A1 (en) 2019-11-07
US20220289737A1 (en) 2022-09-15
ZA201905585B (en) 2020-05-27
MX2019010541A (es) 2019-10-21
WO2018165392A1 (en) 2018-09-13
AU2018231035B2 (en) 2021-09-09
US20190127371A1 (en) 2019-05-02
JP2020510015A (ja) 2020-04-02
AU2018231035A1 (en) 2019-09-05
AR111242A1 (es) 2019-06-19
IL268679A (en) 2019-10-31
AU2018231032A8 (en) 2019-10-17
KR20190127798A (ko) 2019-11-13
US10208040B2 (en) 2019-02-19
EP3592742B1 (en) 2021-05-19
JP7134990B2 (ja) 2022-09-12
EA037748B1 (ru) 2021-05-18
EP3592743A1 (en) 2020-01-15
TWI779016B (zh) 2022-10-01
US11453668B2 (en) 2022-09-27
IL268679B (en) 2021-10-31
US10550118B2 (en) 2020-02-04
US11254669B2 (en) 2022-02-22
MX388750B (es) 2025-03-20
CN110382498A (zh) 2019-10-25
KR102533646B1 (ko) 2023-05-17
ZA201905618B (en) 2021-05-26
PT3592742T (pt) 2021-07-30
CA2997772A1 (en) 2018-09-09
EP3592742A1 (en) 2020-01-15
CN110461839B (zh) 2022-08-23
KR20190127796A (ko) 2019-11-13

Similar Documents

Publication Publication Date Title
US11878977B2 (en) JAK inhibitors containing a 4-membered heterocyclic amide
US11634419B2 (en) Dimethyl amino azetidine amides as JAK inhibitors
US11713315B2 (en) 5 to 7 membered heterocyclic amides as JAK inhibitors
CA3053853C (en) Dimethyl amino azetidine amides and 5 to 7 membered heterocyclic amides as jak inhibitors
EA040464B1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
NZ756823B2 (en) Jak inhibitors containing a 4-membered heterocyclic amide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211029

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211104

R150 Certificate of patent or registration of utility model

Ref document number: 6974487

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250